Edition:
United States

Biotechnology & Medical Research

Page 1

Sarepta Therapeutics reports pricing of $300 million public offering of common stock

Thursday, 22 Sep 2016 06:00pm EDT

Sarepta Therapeutics Inc : Sarepta Therapeutics announces pricing of $300 million public offering of common stock . Says public offering priced at $59.75 per share . Priced public offering of an aggregate of 5.02 million shares of its common stock at a price to public of $59.75/share. .Sarepta Therapeutics announces pricing of $300 million public offering of common stock.

Pentwater Capital reports passive stake of 18.8 pct in Tobira Therapeutics

Thursday, 22 Sep 2016 05:08pm EDT

Tobira Therapeutics Inc :Pentwater Capital Management Lp reports passive stake of 18.8 percent in Tobira Therapeutics inc as of september 20, 2016 - SEC filing.

Uniqure NV says Matthew Kapusta Appointed Interim CEO

Thursday, 22 Sep 2016 04:18pm EDT

Uniqure Nv : "At This Time, Elected Not To Initiate Search Process For Permanent CEO" . Uniqure Announces Management And Board Changes . Says CEO Daniel Soland Resigned . Says Matthew Kapusta Appointed Interim CEO . Kapusta Will Continue To Serve As CFO . Says In Addition, Philip Astley-Sparke Has Been Elected Unanimously By Board To Serve As Its Chairman .Following Soland's Resignation, Company's Board Of Directors Currently Consists Of Seven Members.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary